Paclitaxel, a natural product extracted from the red fir, inhibits tumor cell mitosis by acting on microtubule proteins. It is a typical representative of the paclitaxel class and is the first chemical drug from a natural plant to receive FDA approval for the treatment of a variety of cancers, including ovarian, breast, lung, Kaposi’s sarcoma, cervical and pancreatic cancers. In recent years, paclitaxel has also gained popularity for its use in medical devices. Let’s take a look at it in the following article.
Uses of paclitaxel in medical devices
Paclitaxel, through simultaneous polymerization with α (α-tubulin) and β (β-tubulin) of microtubulin, causes a large number of microtubules to polymerize abnormally, resulting in the alteration of the skeletal equilibrium state of cells and the loss of normal function, causing cell development to stop in G0/G1 phase and G1 and GM phase, and cell mitosis to be prevented in mitotic phase, ultimately achieving the inhibition of vascular smooth muscle division, proliferation The result is to inhibit the division and proliferation of vascular smooth muscle and prevent restenosis from occurring.
1. Paclitaxel drug stent
Drug-eluting stent (DES) is a stent that uses a bare metal stent platform to carry (carry) an anti-endothelial proliferation drug, which is released by local elution in the vessel to effectively inhibit endothelial proliferation in order to prevent restenosis in the stent. The effective use of drug-eluting stents significantly reduced the incidence of restenosis and re-intervention, but did not reduce the rate of morbidity and mortality. There were no significant differences in the incidence of clinical endpoint events between drug-eluting stents, with some secondary endpoints benefiting. Drug-eluting stents include bare stents made of stainless steel or cobalt-chromium that are covered with antiproliferative drug carriers with polymeric drug delivery coatings including permanent, biodegradable, and polymer-free drug delivery coating technologies, and contain drugs including limoxylates and paclitaxel. Currently, paclitaxel drug stents are mainly used in the treatment of various diseases of coronary, intracranial, carotid, renal and femoral arteries.
2. Paclitaxel drug-coated balloons
Drug-coated balloon (DCB), as a new and mature interventional technique, has been proven in several clinical trials for its efficacy and safety in ISR, intracoronary stenosis lesions, small vessel lesions, bifurcation lesions, etc.
Note: The potential efficacy and applications described in this article are derived from published literature.
Extended reading:Yunnan Hande Biotechnology Co., Ltd. has been focusing on the production of paclitaxel for 28 years. It is the world’s first independent manufacturer of the plant-derived anticancer drug paclitaxel that has been approved by the US FDA, European EDQM, Australian TGA, China CFDA, India, Japan and other national regulatory agencies. enterprise. If you want to buy Paclitaxel API, please contact us online.
Post time: Oct-09-2022